Mirum climbs on positive late-stage trial results for liver disease drug
12/10/2026 13:55
BUZZ-Mirum climbs on positive late-stage trial results for liver disease drug ** Mirum Pharmaceuticals MIRM.O shares rise 6.4% to $91.50 premarket
** Set to open highest in ~3 weeks, if gains hold
** Drugmaker says LIVMARLI (maralixibat) drug met late-stage trial primary endpoint in patients with ultra-rare cholestatic liver diseases
** Adds maralixibat reduced pruritus significantly in patients with biliary atresia, cut serum bile acids 69%
** Biliary atresia: Rare liver disease that can cause severe itching (pruritus) due to impaired bile flow
** Plans US supplemental new drug application (sNDA) submission in the H127
** As of last close, MIRM stock up 8.9% YTD
(Reporting by Darshan Kumar in Bengaluru)
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX